The importance of patient engagement in the multimodal treatment of MASLD
World Health Organization. Noncommunicable Diseases (NCD) (WHO, 2019). www.who.int/gho/ncd/mortality_morbidity/en/.
Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7, 851–861 (2022).
Google Scholar
Anstee, Q. M., Targher, G. & Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 10, 330–344 (2013).
Google Scholar
Simon, T. G., Roelstraete, B., Khalili, H., Hagström, H. & Ludvigsson, J. F. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 70, 1375–1382 (2021).
Google Scholar
Shang, Y., Nasr, P., Widman, L. & Hagström, H. Risk of cardiovascular disease and loss in life expectancy in NAFLD. Hepatology 76, 1495–1505 (2022).
Google Scholar
O’Hara, J. et al. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. JHEP Rep. 2, 100142 (2020).
Google Scholar
Younossi, Z. M. et al. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease. JHEP Rep. 6, 101066 (2024). This paper provides a clear message about stigmatization in MASLD.
Google Scholar
Puhl, R. M. Weight stigma and barriers to effective obesity care. Gastroenterol. Clin. North Am. 52, 417–428 (2023).
Google Scholar
Lazarus, J. V. et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat. Rev. Gastroenterol. Hepatol. 19, 60–78 (2022).
Google Scholar
Karlsen, T. H. et al. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 399, 61–116 (2022).
Google Scholar
Akbari, C. et al. Long-term major adverse liver outcomes in 1260 patients with non-cirrhotic NAFLD. JHEP Rep. 6, 100915 (2024).
Google Scholar
Rinella, M. E. et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542–1556 (2023). This paper describes the rationale of the new NAFLD/MASLD nomenclature.
Google Scholar
Phelps, N. H. et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 403, 1027–1050 (2024).
Google Scholar
Grinshpan, L. S. et al. Ultra-processed food consumption and non-alcoholic fatty liver disease, metabolic syndrome and insulin resistance: a systematic review. JHEP Rep. 6, 100964 (2024).
Google Scholar
Budreviciute, A. et al. Management and prevention strategies for non-communicable diseases (NCDs) and their risk factors. Front Public Health 8, 574111 (2020).
Google Scholar
Lazarus, J. V. et al. A global action agenda for turning the tide on fatty liver disease. Hepatology 79, 502–523 (2023).
Google Scholar
Kim, D., Vazquez-Montesino, L. M., Li, A. A., Cholankeril, G. & Ahmed, A. Inadequate physical activity and sedentary behavior are independent predictors of nonalcoholic fatty liver disease. Hepatology 72, 1556–1568 (2020).
Google Scholar
Alemany-Pagès, M. et al. Insights from qualitative research on NAFLD awareness with a cohort of T2DM patients: time to go public with insulin resistance? BMC Public Health 20, 1142 (2020).
Google Scholar
Centis, E. et al. Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. J. Hepatol. 58, 771–777 (2013).
Google Scholar
Wahlin, S. & Andersson, J. Liver health literacy and social stigma of liver disease: A general population e-survey. Clin. Res Hepatol. Gastroenterol. 45, 101750 (2021).
Google Scholar
Madrigal Pharmaceuticals. Madrigal Pharmaceuticals Announces FDA Approval of RezdiffraTM (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis (Madrigal Pharmaceuticals, 2024).
Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390, 497–509 (2024). This paper describes the phase 3 randomized controlled trial of the first approved drug to treat MASH.
Google Scholar
Cusi, K. Nonalcoholic steatohepatitis in nonobese patients: Not so different after all. Hepatology 65, 4–7 (2017).
Google Scholar
World Health Organization. WHO Framework for Meaningful Engagement of People Living with Noncommunicable Diseases, and Mental Health and Neurological Conditions (WHO, 2023).
Montori, V. M., Ruissen, M. M., Hargraves, I. G., Brito, J. P. & Kunneman, M. Shared decision-making as a method of care. BMJ Evid. Based Med. 28, 213–217 (2023).
Google Scholar
Ho, Y. C. L., Mahirah, D., Zhong-Hao Ho, C. & Thumboo, J. The role of the family in health promotion: a scoping review of models and mechanisms. Health Promot. Int. 37, 1–14 (2022).
Google Scholar
Stewart, K. E. et al. Readiness for behaviour change in non-alcoholic fatty liver disease: implications for multidisciplinary care models. Liver Int 35, 936–943 (2015).
Google Scholar
Resnicow, K. & McMaster, F. Motivational interviewing: moving from why to how with autonomy support. Int J. Behav. Nutr. Phys. Act. 9, 15171788 (2012).
Google Scholar
Schattenberg, J. M. et al. A multistakeholder approach to innovations in NAFLD care. Commun. Med. 3, 1 (2023). This paper describes key aspects of the multidisciplinary management of MASLD.
Google Scholar
Kasila, K. et al. Individual differences in processes of lifestyle changes among people with obesity: An acceptance and commitment therapy (ACT) intervention in a primary health care setting. Prim. Health Care Res. Dev. 21, e12 0.1017/S146342362000016X (2020).
Google Scholar
Guerrini Usubini, A. et al. The ACTyourCHANGE study protocol: promoting a healthy lifestyle in patients with obesity with Acceptance and Commitment Therapy—a randomized controlled trial. Trials 22, 290 (2021).
Google Scholar
Vilar-Gomez, E. et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149, 367–378 (2015).
Google Scholar
Mcguire, M. T., Wing, R. R. & Hill, J. O. The prevalence of weight loss maintenance among American adults. Int J. Obes. 23, 1314–1319 (1999).
Google Scholar
Wing, R. R. & Phelan, S. Long-term weight loss maintenance. Am. J. Clin. Nutr. 82, 222S–225S (2005).
Google Scholar
Wing, R. R. & Hill, J. O. Successful weight loss maintenance. Annu Rev. Nutr. 21, 323–341 (2001).
Google Scholar
Nackers, L. M., Ross, K. M. & Perri, M. G. The association between rate of initial weight loss and long-term success in obesity treatment: Does slow and steady win the race? Int J. Behav. Med. 17, 161–167 (2010).
Google Scholar
Ariya, M. et al. Assessment of the association between body composition and risk of non-alcoholic fatty liver. PLoS ONE 16, e0249223 (2021).
Google Scholar
Lazarus, J. V. et al. The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories. Hepatology 78, 911–928 (2023). This paper highlights different societal aspects that contribute to MASLD.
Google Scholar
Mazzotti, A. et al. An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. J. Hepatol. 69, 1155–1163 (2018).
Google Scholar
Pfirrmann, D. et al. Web-based exercise as an effective complementary treatment for patients with nonalcoholic fatty liver disease: intervention study. J. Med. Internet Res. 21, 211250 (2019).
Google Scholar
Tincopa, M. A., Wong, J., Fetters, M. & Lok, A. S. Patient disease knowledge, attitudes and behaviours related to non-alcoholic fatty liver disease: a qualitative study. BMJ Open Gastroenterol. 8, e000634 (2021).
Google Scholar
Ivancovsky-Wajcman, D. et al. Integrating social nutrition principles into the treatment of steatotic liver disease. Commun. Med. 3, 165 (2023).
Google Scholar
Morse, D. F. et al. Global developments in social prescribing. BMJ Glob. Health 7, e008524 (2022).
Google Scholar
Siddiqui, M. S. et al. Prevalence and severity of nonalcoholic fatty liver disease among caregivers of patients with nonalcoholic fatty liver disease cirrhosis. Clin. Gastroenterol. Hepatol. 17, 2132–2133 (2019).
Google Scholar
Gu, Y., Zhang, W., Hu, Y., Chen, Y. & Shi, J. Association between nonalcoholic fatty liver disease and depression: A systematic review and meta-analysis of observational studies. J. Affect Disord. 301, 8–13 (2022).
Google Scholar
Xiao, J. et al. Is fatty liver associated with depression? a meta-analysis and systematic review on the prevalence, risk factors, and outcomes of depression and non-alcoholic fatty liver disease. Front. Med. 8, 691696 (2021).
Google Scholar
Uphoff, E. et al. Behavioural activation therapy for depression in adults with non-communicable diseases. Cochrane Database Syst. Rev. 8, CD013461 (2020).
Google Scholar
Hasnain, M. & Vieweg, W. V. R. Weight considerations in psychotropic drug prescribing and switching. Postgrad. Med. 125, 117–129 (2013).
Google Scholar
Gonzalez, C. L., Azim, S. & Miedlich, S. U. GLP-1 analogs are superior in mediating weight loss but not glycemic control in diabetic patients on antidepressant medications: a retrospective cohort study. Prim. Care Companion CNS Disord. 23, 20m02868 (2021).
Google Scholar
Bak, M. et al. Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: a systematic review and meta-analysis. Acta Psychiatr Scand. In press (2024).
Labenz, C. et al. Nonalcoholic fatty liver disease increases the risk of anxiety and depression. Hepatol. Commun. 4, 1293–1301 (2020).
Google Scholar
Stubbe, D. E. Alleviating anxiety: optimizing communication with the anxious patient. Focus 15, 182–184 (2017).
Google Scholar
Gairing, S. J. et al. Prevalence of minimal hepatic encephalopathy in patients with liver cirrhosis: a multicenter study. Am. J. Gastroenterol. 118, 2191–2200 (2023).
Google Scholar
Stinton, L. M., Jayakumar, S. & Frcpc, M. D. Minimal hepatic encephalopathy. Can. J. Gastroenterol. 27, 572–574 (2013).
Google Scholar
Kjærgaard, K. et al. Cognitive dysfunction in non-alcoholic fatty liver disease—current knowledge, mechanisms and perspectives. J. Clin. Med. 10, 1–20 (2021).
Google Scholar
Amodio, P. et al. Detection of minimal hepatic encephalopathy: normalization and optimization of the psychometric hepatic encephalopathy score. a neuropsychological and quantified EEG study. J. Hepatol. 49, 346–353 (2008).
Google Scholar
Campagna, F. et al. The animal naming test: An easy tool for the assessment of hepatic encephalopathy. Hepatology 66, 198–208 (2017).
Google Scholar
Newsome, P., Rinella, M. E., Lazarus, J. V. & Terrault, N. Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with ‘Ludwig disease’. Hepatology 79, E5–E6 (2024).
Google Scholar
Auckburally, S., Davies, E. & Logue, J. The use of effective language and communication in the management of obesity: the challenge for healthcare professionals. Curr. Obes. Rep. 10, 274–281 (2021).
Google Scholar
Krist, A. H., Tong, S. T., Aycock, R. A. & Longo, D. R. Engaging patients in decision-making and behavior change to promote prevention. Stud. Health Technol. Inf. 240, 284–302 (2017).
Loomba, R. & Adams, L. A. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology 70, 1885–1888 (2019).
Google Scholar
Carrieri, P. et al. Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes. Liver Int. 42, 984–994 (2022).
Google Scholar
Boeckmans, J., Sandrin, L., Knackstedt, C. & Schattenberg, J. M. Liver stiffness as a cornerstone in heart disease risk assessment. Liver Int. 44, 344–356 (2023).
Google Scholar
Mantovani, A. et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut 72, 372–380 (2022).
Google Scholar
Mantovani, A., Byrne, C. D., Bonora, E. & Targher, G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diab. Care 41, 372–382 (2018).
Google Scholar
Boeckmans, J. et al. Inflammation in liver fibrosis and atrial fibrillation: a prospective population-based proteomic study. JHEP Rep. 6, 101171 (2024).
Google Scholar
Mittal, S. et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 14, 124–131.e1 (2016).
Google Scholar
Kanwal, F. et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology 155, 1828–1837.e2 (2018).
Google Scholar
Hagström, H., Shang, Y., Hegmar, H. & Nasr, P. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol. Hepatol. 9, 944–956 (2024).
Google Scholar
Francque, S. M. et al. Non-alcoholic fatty liver disease: a patient guideline. JHEP Rep. 3, 100322 (2021).
Google Scholar
www.globalfattyliverday.com. Consulted June 2024.
Sarkar, M. et al. Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes. J. Hepatol. 73, 516–522 (2020).
Google Scholar
Hagström, H. Maternal obesity increases the risk and severity of NAFLD in offspring. J. Hepatol. 75, 1042–1048 (2021).
Google Scholar
Steitz, B. D. et al. Perspectives of patients about immediate access to test results through an online patient portal. JAMA Netw. Open 6, e233572 (2023).
Google Scholar
Bensing, J. M. et al. How to make the medical consultation more successful from a patient’s perspective? Tips for doctors and patients from lay people in the United Kingdom, Italy, Belgium and the Netherlands. Patient Educ. Couns. 84, 287–293 (2011).
Google Scholar
Vali, Y. et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol. Hepatol. 8, 714–725 (2023). This paper describes the performance of different non-invasive tests for advanced MASLD.
Google Scholar
Mózes, F. E. et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol. Hepatol. 8, 704–713 (2023).
Google Scholar
Sanyal, A. J., Castera, L. & Wong, V. W. S. Noninvasive assessment of liver fibrosis in NAFLD. Clin. Gastroenterol. Hepatol. 21, 2026–2039 (2023).
Google Scholar
Lin, H. et al. Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease. JAMA 331, 1287–1297 (2024).
Google Scholar
Siddiqui, M. S. et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 17, 156–163.e2 (2019).
Google Scholar
Caussy, C., Reeder, S. B., Sirlin, C. B. & Loomba, R. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology 68, 763–772 (2018).
Google Scholar
Liang, J. X. et al. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. J. Hepatol. 79, 592–604 (2023).
Google Scholar
Ajmera, V. & Loomba, R. Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol. Metab. 50, 101167 (2021).
Google Scholar
McKay, A. et al. Patient understanding and experience of non-invasive imaging diagnostic techniques and the liver patient pathway. J. Patient Rep. Outcomes 5, 89 (2021).
Google Scholar
Anstee, Q. M. et al. Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and/or type 2 diabetes: a longitudinal cohort study. Lancet Reg. Health Eur. 36, 100780 (2024).
Google Scholar
Houts, P. S., Doak, C. C., Doak, L. G. & Loscalzo, M. J. The role of pictures in improving health communication: a review of research on attention, comprehension, recall, and adherence. Patient Educ. Couns. 61, 173–190 (2006).
Google Scholar
Targher, G., Byrne, C. D. & Tilg, H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 73, 691–702 (2024).
Google Scholar
Boeckmans, J. et al. Clinical utility of the Fibrosis-4 index for predicting mortality in patients with heart failure with or without metabolic dysfunction-associated steatotic liver disease: a prospective cohort study. Lancet Reg. Health Eur. 48, 101153 (2025).
Google Scholar
Allen, L. et al. Socioeconomic status and non-communicable disease behavioural risk factors in low-income and lower-middle-income countries: a systematic review. Lancet Glob. Health 5, e277–e289 (2017). This paper highlights societal aspects of non-communicable disease.
Google Scholar
Vilar-Gomez, E. et al. High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population. Hepatology 75, 1491–1506 (2022).
Google Scholar
Zelber-Sagi, S. et al. Food inequity and insecurity and MASLD: burden, challenges, and interventions. Nat. Rev. Gastroenterol. Hepatol. 21, 668–686 (2024).
Google Scholar
Richard, V. et al. Socioeconomic inequalities in sport participation: pattern per sport and time trends – a repeated cross-sectional study. BMC Public Health 23, 785 (2023).
Google Scholar
McMaughan, D. J., Oloruntoba, O. & Smith, M. L. Socioeconomic status and access to healthcare: interrelated drivers for healthy aging. Front. Public Health 8, 231 (2020).
Google Scholar
Lazarus, J. V. et al. NAFLD — sounding the alarm on a silent epidemic. Nat. Rev. Gastroenterol. Hepatol. 17, 377–379 (2020).
Google Scholar
Boeckmans, J. et al. PNPLA3 I148M and response to treatment for hepatic steatosis: a systematic review. Liver Int 43, 975–988 (2023).
Google Scholar
Rich, N. E. et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 16, 198–210.e2 (2018).
Google Scholar
Riazi, K., Swain, M. G., Congly, S. E., Kaplan, G. G. & Shaheen, A. A. Race and ethnicity in non-alcoholic fatty liver disease (NAFLD): a narrative review. Nutrients 14, 4556 (2022).
Google Scholar
Vijay, A. et al. Development of food group tree-based analysis and its association with non-alcoholic fatty liver disease (NAFLD) and co-morbidities in a South Indian population: a large case-control study. Nutrients 14, 2808 (2022).
Google Scholar
Yasutake, K. et al. Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World J. Gastroenterol. 20, 1756–1767 (2014).
Google Scholar
Miwa, T. et al. Usefulness of a questionnaire for assessing the relationship between eating behavior and steatotic liver disease among Japanese male young adults. Sci. Rep. 14, 2194 (2024).
Google Scholar
Pavithran, N. et al. The effect of a low GI diet on truncal fat mass and glycated hemoglobin in South Indians with type 2 diabetes—a single centre randomized prospective study. Nutrients 12, 179 (2020).
Google Scholar
Islam, N. S. et al. A culturally tailored community health worker intervention leads to improvement in patient-centered outcomes for immigrant patients with type 2 diabetes. Clin. Diab. 36, 100–111 (2018).
Google Scholar
Farhat, G. Culturally tailored dietary interventions for improving glycaemic control and preventing complications in South Asians with type 2 diabetes: success and future implications. Healthcare 11, (2023).
Aggarwal, A., Tam, C. C., Wu, D., Li, X. & Qiao, S. Artificial intelligence–based chatbots for promoting health behavioral changes: systematic review. J. Med. Internet Res. 25, e40789 (2023).
Google Scholar
Burton, R. & Sheron, N. No level of alcohol consumption improves health. Lancet 392, 987–988 (2018).
Google Scholar
Dunn, W. et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J. Hepatol. 57, 384–391 (2012).
Google Scholar
Jarvis, H. et al. Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis. BMJ Open 12, 12 (2022).
Google Scholar
Kimura, T. et al. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fbrosis. World J. Gastroenterol. 24, 1440–1450 (2018).
Google Scholar
Spence, A. D., Khasawneh, M., Allen, P. B. & Addley, J. Communication of alcohol and smoking lifestyle advice to the gastroenterological patient. Best. Pr. Res Clin. Gastroenterol. 31, 597–604 (2017).
Google Scholar
Prestwich, A. et al. Does changing social influence engender changes in alcohol intake? A meta-analysis. J. Consult Clin. Psychol. 84, 845–860 (2016).
Google Scholar
McCormick, K. A. et al. How primary care providers talk to patients about alcohol. J. Gen. Intern Med. 9, 966–972 (2006).
Google Scholar
Sen, B., Goldfarb, S. & Tarver, W. Family structure and risk behaviors: the role of the family meal in assessing likelihood of adolescent risk behaviors. Psychol. Res Behav. Manag. 7, 52–66 (2014).
Rezayat, A. A. et al. Association between smoking and non-alcoholic fatty liver disease: a systematic review and meta-analysis. SAGE Open Med. 6, 2050312117745223 (2018).
Google Scholar
Okamoto, M. et al. Cigarette smoking is a risk factor for the onset of fatty liver disease in nondrinkers: A longitudinal cohort study. PLoS ONE 13, e0195147 (2018).
Google Scholar
Chen, B. et al. Gut bacteria alleviate smoking-related NASH by degrading gut nicotine. Nature 610, 562–568 (2022).
Google Scholar
Pirie, K., Peto, R., Reeves, G. K., Green, J. & Beral, V. The 21st century hazards of smoking and benefits of stopping: A prospective study of one million women in the UK. Lancet 381, 133–141 (2013).
Google Scholar
Evans-Polce, R. J., Castaldelli-Maia, J. M., Schomerus, G. & Evans-Lacko, S. E. The downside of tobacco control? Smoking and self-stigma: a systematic review. Soc. Sci. Med 145, 26–34 (2015).
Google Scholar
Balogun, O. et al. Effect of combined tobacco use and type 2 diabetes mellitus on prevalent fibrosis in patients with MASLD. Hepatol. Commun. 7, e0300 (2023).
Google Scholar
Epstein, R. M. et al. Measuring patient-centered communication in patient-physician consultations: theoretical and practical issues. in. Soc. Sci. Med. 61, 1516–1528 (2005).
Google Scholar
May, C. R., Montori, V. M. & Mair, F. S. We need minimally disruptive medicine. BMJ 339, b2803 (2009).
Google Scholar
Gross, D. A. et al. Patient satisfaction with time spent with their physician. J. Fam. Pr. 47, 133–137 (1998).
Google Scholar
Levinson, W. & Pizzo, P. A. Patient-physican communication it’s about time. JAMA. 305, 1802–1803 (2011).
El-Haddad, C., Hegazi, I. & Hu, W. Understanding patient expectations of health care: a qualitative study. J. Patient Exp. 7, 1724–1731 (2020).
Google Scholar
Kurnik Mesarič, K., Pajek, J., Logar Zakrajšek, B., Bogataj, Š. & Kodrič, J. Cognitive behavioral therapy for lifestyle changes in patients with obesity and type 2 diabetes: a systematic review and meta-analysis. Sci. Rep. 13, 12793 (2023).
Google Scholar
Tilg, H., Byrne, C. D. & Targher, G. NASH drug treatment development: challenges and lessons. Lancet Gastroenterol. Hepatol. 8, 943–954 (2023).
Google Scholar
Arterburn, D. E., Telem, D. A., Kushner, R. F. & Courcoulas, A. P. Benefits and risks of bariatric surgery in adults: a review. JAMA 324, 879–887 (2020).
Google Scholar
Harrison, S. A. et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat. Med. 29, 2919–2928 (2023).
Google Scholar
Newsome, P. N. & Ambery, P. Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver. J. Hepatol. 79, 1557–1565 (2023).
Google Scholar
Polyzos, S. A., Vachliotis, I. D. & Mantzoros, C. S. Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease. Metabolism 147, 155676. 0.1016/j.metabol.2023.155676 (2023).
Google Scholar
FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval (2024). Consulted June 2024.
Younossi, Z. M., Stepanova, M., Taub, R. A., Barbone, J. M. & Harrison, S. A. Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life. Clin Gastroenterol Hepatol. 6, 1354–1361.e7 (2022). This paper describes the impact of Resmetirom treatment on quality of life in metabolic dysfunction-associated steatohepatitis.
Wrosch, C. & Scheier, M. F. Personality and quality of life: the importance of optimism and goal adjustment. Qual. Life Res. 12, 59–72 (2003).
Google Scholar
Younossi, Z. et al. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes. JHEP Rep. 4, 100525 (2022). This paper describes patient-reported outcomes in MASLD.
Google Scholar
Popoviciu, M. S., Păduraru, L., Yahya, G., Metwally, K. & Cavalu, S. Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials. Int J. Mol. Sci. 24, 10449 (2023).
Google Scholar
Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 (2021).
Google Scholar
Newsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic Steatohepatitis. N. Engl. J. Med. 384, 1113–1124 (2021). This paper describes a phase 2 randomized trial of a GLP-1 agonist in MASH.
Google Scholar
Bessesen, D. H. & Van Gaal, L. F. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diab. Endocrinol. 6, 237–248 (2018).
Google Scholar
Waldrop, S. W., Johnson, V. R. & Stanford, F. C. Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity. Nat. Med. 30, 22–25 (2024).
Google Scholar
Krag, A. et al. Uniting to defeat steatotic liver disease: a global mission to promote healthy livers and healthy lives. J. Hepatol. 79, 1076–1078 (2023).
Google Scholar
Global Liver Institute. Liver Health is Public Health initiative (Global Liver Institute, 2024). www.globalliver.org/liver-health-is-public-health.
Rinella, M. E. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77, 1797–1835 (2023).
Google Scholar
Verma, M. et al. Patient-centered care: Key elements applicable to chronic liver disease. Hepatology 78, 307–318 (2023).
Google Scholar
Caussy, C. et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology 67, 1348–1359 (2018).
Google Scholar
Bedogni, G. et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 6, 1–7 (2006).
Google Scholar
Lonardo, A., Ballestri, S., Bedogni, G., Bellentani, S. & Tiribelli, C. The Fatty liver Index (FLI) 15 years later: a reappraisal. Metab. Target Organ Damage 1, 10 (2021).
Google Scholar
Fedchuk, L. et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharm. Ther. 40, 1209–1222 (2014).
Google Scholar
Hernaez, R. et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 54, 1082–1090 (2011).
Google Scholar
Strauss, S., Gavish, E., Gottlieb, P. & Katsnelson, L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am. J. Roentgenol. 189, W320–W323 (2007).
Google Scholar
Cao, Y.-T. et al. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. EclinicalMedicine 51, 101547 (2022).
Google Scholar
Sirli, R. & Sporea, I. Controlled attenuation parameter for quantification of steatosis: Which cut-offs to use? Can. J. Gastroenterol. Hepatol. 2021, 6662760 (2021).
Google Scholar
McPherson, S. et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am. J. Gastroenterol. 112, 740–751 (2017).
Google Scholar
Blackard, J. T. et al. HIV mono-infection is associated with FIB-4—a noninvasive index of liver fibrosis—in women. Clin. Infect. Dis. 52, 674–680 (2011).
Google Scholar
Shah, A. G. et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 7, 1104–1112 (2009).
Google Scholar
Angulo, P. et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45, 846–854 (2007).
Google Scholar
Vali, Y. et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. J. Hepatol. 73, 252–262 (2020).
Google Scholar
Lichtinghagen, R. et al. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J. Hepatol. 59, 236–242 (2013).
Google Scholar
Wong, V. W. S. et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am. J. Gastroenterol. 107, 1862–1871 (2012).
Google Scholar
Gaia, S. et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J. Hepatol. 54, 64–71 (2011).
Google Scholar
Petta, S. et al. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. Hepatology 65, 1145–1155 (2017).
Google Scholar
link
